Theravance Biopharma (TBPH) Equity Ratio (2013 - 2026)

Theravance Biopharma (TBPH) has 14 years of Equity Ratio data on file, last reported at 0.62 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.62, up 27.36% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.62 (up 27.36% YoY), and the FY2025 annual result was 0.61, up 23.29% from the prior year.
• Equity Ratio climbed to 0.62 in Q1 2026 per TBPH's latest filing, from 0.61 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.73 in Q4 2022 and troughed at 0.99 in Q1 2022.
• A 5-year average of 0.4 and a median of 0.56 in 2023 frame the typical range for Equity Ratio.
• On a YoY basis, Equity Ratio climbed as much as 180.52% in 2022 and fell as far as 38.57% in 2022.
• A 5-year view of Equity Ratio shows it stood at 0.73 in 2022, then declined by 23.34% to 0.56 in 2023, then retreated by 11.1% to 0.5 in 2024, then advanced by 23.29% to 0.61 in 2025, then climbed by 0.68% to 0.62 in 2026.
• Business Quant data shows TBPH's Equity Ratio at 0.62 in Q1 2026, 0.61 in Q4 2025, and 0.56 in Q3 2025.